Clinical trial
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
NCT00314132 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00314132 |
|---|---|
| Title | Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. |
| Official title | Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE) |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Encephalitis, Japanese Encephalitis |
| Intervention type | Biological |
| Interventions | ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline |
| Enrollment | 2,004 |
| Start date | Oct 1, 2005 |
| Primary completion | Nov 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | Apr 13, 2006 |
| Last update posted | Dec 6, 2012 |
| Countries | Australia, United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: